Bharat Biotech Vaccine Gets Expert Panel Approval – Everything You Need to Know About Covaxin’s Efficacy and Price
In addition to the Oxford / Astrazeneca vaccine, the other candidate vaccine that is set to gain restricted approval for emergency use in the coming days is Covaxin from Bharat Biotech. The Indian drug regulator’s panel of subject matter experts recommended it for emergency use on Saturday. While final nod goes to the Controller General of Drugs of India (DCGI), the fact that Covaxin comes one step closer to obtaining approval is of great importance to India on the global stage as the vaccine is has developed in India.
This is everything you need to know about this vaccine:
Vaccine made in India: This is the first vaccine manufactured in India developed by Bharat Biotech in collaboration with the Indian Council for Medical Research and the National Institute of Virology.
An inactivated one that develops by inactivating (killing) the living microorganisms that cause disease. This destroys the pathogen’s ability to replicate, but keeps it intact so the immune system can still recognize it and produce an immune response. There are many inactivated vaccines against hepatitis A, influenza, polio and rabies, which offer “excellent protection”, said Bharat Biotech.
Expert Panel Recommends Covaxin from Bharat Biotech for Restricted Emergency Use
Covaxin efficacy proven in animal studies
Bharat Biotech in their report published after animal studies said that their vaccine candidate showed protective efficacy. The candidate vaccine was administered to 20 rhesus macaques, divided into four groups. One group was given a placebo, while three other groups were immunized with three different candidate vaccines. “To summarize, the candidate vaccine was found to generate strong immune responses. Therefore, infection and disease in primates is prevented after large amounts of exposure to the live SARS-CoV-2 virus, ”he said.
Covaxin Human Clinical Trial Results
The third phase of the test is still in progress, while the company has already published the results of the first two rounds. It followed a double-linked, randomized, multicenter phase two clinical trial that also included children.
The effectiveness will be determined only after two shots
After Haryana Minister Anil Vij tested positive after receiving one dose of the vaccine during the trial, the company clarified that efficacy will be determined only after 14 days after the second dose. Also, as their trial was randomized in which some received the vaccine and others received placebo, there was no way to know whether the minister received a vaccine injection or a placebo injection.
The union’s health minister, Dr. Harsh Vardhan, clarified on Saturday that the first phase of vaccination that will include frontline workers will be free. The price of Covaxin has not been talked about, although Dr. Krishna Ella, MD of Bharat Biotech, previously said that the vaccine will be cheap, cheaper than a bottle of water, he said at a conference, pointing to a bottle of water. Since your comment, it has been estimated that it will cost less than Rs 100.